Immunogen | IMGN - Прибыль до налогообложения



Прибыль до налогообложения Изменить Дата
AbbVie USD 5.57B 2.9B 2026-03
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Amgen USD 1.51B 2.41B 2025-12
Astellas Pharma JPY 48.02B 85.93B 2026-03
AstraZeneca USD 3.91B 1.28B 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Exelixis USD 267.69M 15M 2026-03
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Intrexon USD -60.48M 27.09M 2024-06
Karyopharm Therapeutics USD -39.9M 9.01M 2025-12
MacroGenics USD -14.93M 31.75M 2025-12
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Novartis USD 5.17B 637M 2025-09
Pfizer USD 5.18B 6.82B 2026-03
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Sanofi EUR -1.16B 6.23B 2025-12